| Verified against primary record | |
| Approved stem cell products in the United States | Only blood-forming stem cells from umbilical cord blood, for disorders affecting blood production[1] |
|---|---|
| Regulator’s test for deception | Being charged for such a product, or offered it outside a trial under regulatory oversight, likely means an illegal product[1] |
| Registration is not approval | Listing on a trial registry, or registration with the regulator, does not mean a product is legally marketed[1] |
| Independently reported | |
| Advertising into another country | A clinic in one country advertising to consumers in another is judged against the receiving country’s evidence standards for the health claim[2] |
| Bands apply only to the rows beneath them. The advertising row describes a ruling about advertising directed at consumers in one country, not about the practice of medicine in the clinic’s own country. | |
Experimental treatment is treatment whose safety and effectiveness have not been established for the use proposed. In medical travel the term is frequently used as a selling point rather than a warning, and the regulatory boundary between an experimental treatment and an illegally marketed product is both precise and often crossed.
Where the regulatory line falls
The American biologics regulator states the position for the field in which this question arises most: the only stem cell products approved in the United States are blood-forming stem cells derived from umbilical cord blood, approved only for disorders affecting blood production and not approved for other uses. Such products require licensure before being marketed to consumers, and before approval must be studied under regulatory oversight in a clinical trial. The agency states that these products are often illegally marketed by clinics as safe and effective for many diseases without adequate study, that being charged for such a product or being offered it outside an overseen clinical trial likely means a person is being deceived and offered an illegal product, and that listing on a trial registry or registration with the agency does not mean a product is legally marketed. The safety concerns it names include blindness, tumour formation, neurological events, serious infections and immune reactions.[1]
A current enforcement letter sets out the full legal chain. An umbilical cord-derived cell product marketed for sports injuries, anti-ageing, spinal cord injury, joint pain, cardiovascular disease and arthritis is, on those intended-use claims, a drug and a biological product. As a human cell or tissue product it fails the conditions for exemption because it is not minimally manipulated, processing the cord into injectable form having altered its relevant characteristics, and because treating cardiovascular disease or arthritis is not the basic function the cord performed in the donor. It is therefore a misbranded drug for lacking adequate directions for use, misbranded while held for sale after shipment, and unlawfully marketed without an approved licence application, which requires a showing that the product is safe, pure and potent. The same letter warns that exosome products intended to treat disease are subject to the same requirements including premarket review.[3]
The marketing structures involved mirror those of medical travel. An earlier enforcement action concerned a company operating through more than 50 affiliated centres offering non-approved stem cell products for conditions including Lyme disease, diabetes, Parkinson’s disease, stroke, kidney failure, dementia, rheumatoid arthritis and spinal stenosis, and directing patients to branded centres of excellence; the agency’s leadership stated that such campaigns take advantage of vulnerable patients and their families with unproven claims, and that there is not enough evidence to support stem cell use beyond blood and immune system reconstitution.[4]
Advertising across borders is regulated where it lands
The most directly relevant enforcement case for medical travel concerns advertising rather than treatment. A Turkish clinic ran paid social and search advertising targeting United Kingdom consumers, offering stem cell treatment for children with autism and claiming a 94 per cent success rate and that it could stop the progression of autism. The British advertising regulator ruled the advertisements misleading and unsubstantiated, breaching rules on misleading advertising, substantiation and health-related claims. The clinic’s claims rested on internal patient data the regulator did not see, and the regulator held that an internal report would not match clinical-trial quality and so was unlikely to substantiate the advertisements; it noted that national health guidance indicates autism has no cure and that stem cell transplants are not a recognised treatment for autism in children. The advertisements must not appear again in that form.[2]
The principle is worth stating carefully. The regulator’s jurisdiction attached to advertising aimed at consumers in its own country, not to the treatment delivered abroad, and it set no looser evidence standard because the treatment was overseas. It did not and could not regulate the clinic’s practice in Turkey.
The field’s own framing
A professional white paper proposes the distinction this entry rests on: controlled clinical trials differ from ethically conducted medical innovation, and both differ from fraudulent practice, with the three described as points on a continuum rather than a strict binary. It records that patients travel abroad for cell therapies to clinics whose safety and efficacy claims rest on testimonials and anecdotes, driven by ageing populations, high treatment costs, internet marketing and permissive or unenforced foreign regulation; that unproven cell products can cause serious harm, delay effective care and leave patients without legal recourse; and it proposes assessment criteria for patients, including peer-reviewed evidence, the reputation and disciplinary record of the clinic, and whether consent covers risks, costs, compensation for injury, conflicts of interest and alternatives.[5] The field’s principal professional standard exists in a versioned form with a section on clinical translation of stem cell-based interventions.[6]
A scholarly account of the practice describes patients travelling abroad for unproven stem cell-based interventions, often to countries with less developed medical infrastructure and weaker regulatory oversight, and records documented harms including tumours after fetal stem cell injections, a catastrophic demyelinating reaction after treatment for multiple sclerosis, and deaths after procedures in two further countries; it notes that patients often do not know what cells or dose they received, that follow-up is inconsistent or absent, that the resulting data is unsuitable for research, and that unclear insurance coverage can leave patients paying to treat side effects. Its cost figures, an average around 47,000 United States dollars with a range from about 3,500 to 400,000 plus travel, and its statement that by some calculations more than 40 per cent of patients are minors, are secondary citations within a 2015 debate article whose authors state that the true number of clinics and travelling patients is unknown.[7] Those figures are reproduced here with their date and their provenance and should not be presented as current measurements.
Even the permissive routes require a regulated product
The most permissive American access pathway still presupposes a product inside the regulatory system. An eligible investigational drug must have completed a first-phase clinical trial, must not be approved for any use, must be the subject of an active investigational application with either a filed application or an ongoing trial intended as the primary basis for an effectiveness claim, and must remain in active development and not be on hold; the patient must have a life-threatening disease, have exhausted approved options, be unable to join a trial, and give written informed consent.[8] The clinic products described above satisfy none of this, which is the practical difference between an experimental treatment and an unapproved one sold at a market price.
See also
- Stem Cell Tourism, the travel pattern this regulatory boundary was largely written for
- Clinical Trials Abroad, the legitimate route to an unapproved product, and why charging distinguishes them
- Compassionate Use of Medicines, the pathway for unauthorised products outside a trial
- Medical Travel for Unavailable Treatments, the broader category patients place these journeys in
References
- United States Food and Drug Administration, Center for Biologics Evaluation and Research. Important patient and consumer information about regenerative medicine therapies. Posted 3 June 2021; content current as of 8 April 2024. Verified against primary record: the page was opened and the statements on approved products, charging, registration and named safety concerns read. The page does not mention travel abroad. Retrieved 10 October 2026.
- Advertising Standards Authority. Ruling on Estheturk Danismanlik A.S. trading as You Clinic Turkey. 23 September 2026. Verified against primary record: the ruling was opened and the claims, the breaches found, the reasoning on internal data and the sanction read. Retrieved 10 October 2026.
- United States Food and Drug Administration, Center for Biologics Evaluation and Research. Warning letter to Dynamic Stem Cell Therapy. Reference 712579, dated 11 February 2026; published 24 February 2026. Verified against primary record: the letter was opened and the intended-use claims, the minimal-manipulation and homologous-use findings, the misbranding grounds and the licensing requirement read. Retrieved 10 October 2026.
- United States Food and Drug Administration. FDA puts company on notice for marketing unapproved stem cell products for treating serious conditions. 30 May 2019. Verified against primary record: the announcement was opened and the affiliated-centre structure, the conditions advertised and the quoted official positions read. Retrieved 10 October 2026.
- Gunter KC, Caplan AL, Mason C, Salzman R, Janssen WE, Nichols K, Bouzas LF, Lanza F, Levine BL, Rasko JEJ, Shimosaka A, Horwitz E. Cell therapy medical tourism: time for action. International Society for Cellular Therapy white paper, Cytotherapy 2010;12:965-968. Verified against primary record: the paper was opened and the continuum framing and the proposed patient assessment criteria read. It is a position statement rather than an empirical study. Retrieved 10 October 2026.
- International Society for Stem Cell Research. Guidelines for stem cell research and clinical translation. Version 1.2, August 2025 update. Independently reported: the landing page was opened and the existence, versioning and section structure confirmed; the guidelines document itself was not opened, so no specific position is attributed to it here. Retrieved 10 October 2026.
- Matthews KRW, Iltis AS. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders. BMC Medical Ethics 2015;16:75, 4 November 2015. Verified against primary record: the article was opened and the description of the practice, the documented harms and the cost and patient-age figures read, together with the authors’ statement that the scale is unknown. The cost and proportion figures are secondary citations within this article. Retrieved 10 October 2026.
- United States Food and Drug Administration. Right to Try. Content current as of 12 December 2024. Verified against primary record: the page was opened and the eligibility criteria for the drug and for the patient read. Retrieved 10 October 2026.
Sourcing note: the cost and patient-age figures in the penultimate section are reproduced with their 2015 date because they are the only published figures located, and because their own authors state that the number of clinics and travelling patients is unknown. The professional guidelines are cited for their existence only, because the section bearing on unproven interventions was not accessible from the landing page consulted. No regulator statement was located addressing experimental treatment specifically in a cross-border context; the advertising ruling cited concerns advertising directed into one country, not practice in another.